Key result
The NeoVas sirolimus-eluting bioresorbable stent is safe and efficacious for treating de novo coronary artery disease, though long-term safety may depend on patient and lesion factors.
While the NeoVas bioresorbable stent shows safety and efficacy in de novo coronary artery disease, further research is needed to understand its long-term safety and role in complex lesions.
Key Points The NeoVas sirolimus‐eluting bioresorbable stent is safe and efficacious for treating de novo coronary artery disease. Lesion and patient‐specific characteristics may play a role in the long‐term safety profile of bioresorbable stents. The role of bioresorbable scaffolds in complex coronary lesions needs to be further elucidated.
No takes yet. Share an insight, caveat, or question.
Hajj et al. (2023) studied this question. The NeoVas sirolimus-eluting bioresorbable stent is safe and efficacious for treating de novo coronary artery disease, though long-term safety may depend on patient and lesion factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: